Recent Posts
- Ukraine recovery should be based on development of territorial communities, innovations, involvement of professional domestic community – results of ESUR forum 29.06.2023
- Ukraine repatriates five more seriously wounded Russian POWs 10.04.2023
- Rada intends to include history of Ukraine, foreign language in final certification for general secondary education 10.04.2023
- Rada terminates protocol on joint anti-terrorist measures in CIS territories for Ukraine 10.04.2023
- 100 Ukrainians, incl defenders of Mariupol, returned according to swap procedure – Yermak 10.04.2023
Farmak opens representative office in Vietnam and UAE in 2022
KYIV. Jan 9 (Interfax-Ukraine) – Farmak pharmaceutical company in 2022 expanded its presence in international markets, opened a representative office in Vietnam and an office in the UAE.
According to its press release, last year Farmak exported more than 240 types of products to more than 30 countries of the world, in particular to the countries of the EU, Central and South America, the CIS, the Middle East, and Asia.
As reported, Farmak plans to open a new plant in Barcelona in 2024 and a multifunctional laboratory complex with an R&D center for the development and testing of new medicines in Spain.
Farmak is the leader of the pharmaceutical market of Ukraine in terms of sales of medicines in monetary terms. The company has a pharmaceutical plant in Kyiv and a plant for the production of active pharmaceutical ingredients in Shostka (Sumy region).
The company’s product portfolio includes more than 450 medicines. Among the main areas are endocrinological, gastroenterological, cardiological, neurological, anti-cold and other drugs. The company annually reinvests up to 90% of profits in development. Currently, Farmak’s products are represented in more than 40 countries of the EU, Central and South America, the CIS, the Middle East, Asia, etc.
According to the unified state register of legal entities and individual entrepreneurs, the ultimate beneficial owner of Farmak is the head of the supervisory board, Filya Zhebrovska, who owns 80% of the company’s shares.
